EditorialEditorial

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer

Qi Zhang, Jian Li, Lin Shen, Yongsheng Li and Xicheng Wang
Cancer Biology & Medicine October 2023, 20 (10) 706-712; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0240

References

  1. 1.↵
    2. Jung G,
    3. Hernández-Illán E,
    4. Moreira L,
    5. Balaguer F,
    6. Goel A.
    Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020; 17: 111–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Sinicrope FA.
    Lynch syndrome-associated colorectal cancer. N Engl J Med. 2018; 379: 764–73.
    OpenUrlPubMed
  3. 3.↵
    2. Llosa NJ,
    3. Cruise M,
    4. Tam A,
    5. Wicks EC,
    6. Hechenbleikner EM,
    7. Taube JM, et al.
    The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015; 5: 43–51.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    2. Lipson EJ,
    3. Sharfman WH,
    4. Drake CG,
    5. Wollner I,
    6. Taube JM,
    7. Anders RA, et al.
    Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013; 19: 462–8.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Le DT,
    3. Kim TW,
    4. van Cutsem E,
    5. Geva R,
    6. Jäger D,
    7. Hara H, et al.
    Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020; 38: 11–9.
    OpenUrlCrossRefPubMed
  6. 6.
    2. Le DT,
    3. Durham JN,
    4. Smith KN,
    5. Wang H,
    6. Bartlett BR,
    7. Aulakh LK, et al.
    Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357: 409–13.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. André T,
    3. Lonardi S,
    4. Wong KYM,
    5. Lenz HJ,
    6. Gelsomino F,
    7. Aglietta M, et al.
    Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022; 33: 1052–60.
    OpenUrlPubMed
  8. 8.
    2. Overman MJ,
    3. Lonardi S,
    4. Wong KYM,
    5. Lenz H-J,
    6. Gelsomino F,
    7. Aglietta M, et al.
    Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): long-term follow-up. J Clin Oncol. 2019; 37: 635.
    OpenUrl
  9. 9.
    2. Li J,
    3. Xu Y,
    4. Zang A,
    5. Gao Y,
    6. Gao Q,
    7. Zhang Y, et al.
    Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors. J Clin Oncol. 2022; 40: 1.
    OpenUrl
  10. 10.
    2. Li J,
    3. Deng Y,
    4. Zhang W,
    5. Zhou A-P,
    6. Guo W,
    7. Yang J, et al.
    Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021; 14: 95.
    OpenUrl
  11. 11.
    2. Qin S,
    3. Li J,
    4. Zhong H,
    5. Jin C,
    6. Chen L,
    7. Yuan X, et al.
    Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022; 127: 2241–8.
    OpenUrl
  12. 12.↵
    2. André T,
    3. Shiu K-K,
    4. Kim TW,
    5. Jensen BV,
    6. Jensen LH,
    7. Punt C, et al.
    Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020; 383: 2207–18.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Lenz H-J,
    3. van Cutsem E,
    4. Luisa Limon M,
    5. Wong KYM,
    6. Hendlisz A,
    7. Aglietta M, et al.
    First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J Clin Oncol. 2022; 40: 161–70.
    OpenUrlCrossRef
  14. 14.↵
    2. De Roock W,
    3. Claes B,
    4. Bernasconi D,
    5. De Schutter J,
    6. Biesmans B,
    7. Fountzilas G, et al.
    Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753–62.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Salem M,
    3. André T,
    4. El-Refai S,
    5. Kopetz S,
    6. Tabernero J,
    7. Sinicrope F, et al.
    Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC). J Clin Oncol. 2022; 40: 3066.
    OpenUrl
  16. 16.↵
    2. Salem M,
    3. Kopetz S,
    4. El-Refai S,
    5. Tabernero J,
    6. Sinicrope F,
    7. Tie J, et al.
    Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers. J Clin Oncol. 2022; 40: 3066.
    OpenUrl
  17. 17.↵
    2. Chida K,
    3. Kawazoe A,
    4. Kawazu M,
    5. Suzuki T,
    6. Nakamura Y,
    7. Nakatsura T, et al.
    A low tumor mutational burden and PTEN mutations are predictors of a negative response to PD-1 blockade in MSI-H/dMMR gastrointestinal tumors. Clin Cancer Res. 2021; 27: 3714–24.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Wang Z,
    3. Zhang Q,
    4. Qi C,
    5. Bai Y,
    6. Zhao F,
    7. Chen H, et al.
    Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer. J Immunother Cancer. 2022; 10: e004703.
  19. 19.↵
    2. Bortolomeazzi M,
    3. Keddar MR,
    4. Montorsi L,
    5. Acha-Sagredo A,
    6. Benedetti L,
    7. Temelkovski D, et al.
    Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts. Gastroenterology. 2021; 161: 1179–93.
    OpenUrlPubMed
  20. 20.↵
    2. Chen M,
    3. Wang Z,
    4. Liu Z,
    5. Liu N,
    6. Fang W,
    7. Zhang H, et al.
    The optimal therapy after progression on immune checkpoint inhibitors in MSI metastatic gastrointestinal cancer patients: a multicenter retrospective cohort study. Cancers (Basel). 2022; 14: 5158.
    OpenUrl
  21. 21.↵
    2. Morris V,
    3. Lam M,
    4. Wang X,
    5. Overman M,
    6. Johnson B,
    7. Kee B, et al.
    Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy. J Clin Oncol. 2021; 39: 79.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Hollebecque A,
    3. Chung H,
    4. Miguel M,
    5. Italiano A,
    6. Machiels J-P,
    7. Lin C-C, et al.
    Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability–high/mismatch repair–deficient tumors. Clin Cancer Res. 2021; 27: clincanres.0261.2021.
  23. 23.↵
    2. Morton D,
    3. Seymour M,
    4. Magill L,
    5. Handley K,
    6. Glasbey J,
    7. Glimelius B, et al.
    Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023; 41: 1541–52.
    OpenUrl
  24. 24.↵
    2. Chalabi M,
    3. Fanchi LF,
    4. Dijkstra KK,
    5. van den Berg JG,
    6. Aalbers AG,
    7. Sikorska K, et al.
    Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020; 26: 566–76.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Chalabi M,
    3. Verschoor Y,
    4. Berg J,
    5. Sikorska K,
    6. Beets G,
    7. Lent AV, et al.
    LBA7 neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study. Ann Oncol. 2022; 33: S1389.
    OpenUrl
  26. 26.↵
    2. de Rosa N,
    3. Rodriguez-Bigas MA,
    4. Chang GJ,
    5. Veerapong J,
    6. Borras E,
    7. Krishnan S, et al.
    DNA mismatch repair deficiency in rectal cancer: benchmarking its impact on prognosis, neoadjuvant response prediction, and clinical cancer genetics. J Clin Oncol. 2016; 34: 3039–46.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    2. Cercek A,
    3. Lumish M,
    4. Sinopoli J,
    5. Weiss J,
    6. Shia J,
    7. Lamendola-Essel M, et al.
    PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022; 386: 2363–76.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Chen G,
    3. Jin Y,
    4. Guan W-L,
    5. Zhang R-X,
    6. Xiao W-W,
    7. Cai P-Q, et al.
    Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023; 8: 422–31.
    OpenUrl
  29. 29.↵
    2. Hu H,
    3. Kang L,
    4. Zhang J,
    5. Wu Z,
    6. Wang H,
    7. Huang M, et al.
    Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022; 7: 38–48.
    OpenUrl
  30. 30.↵
    2. Dighe S,
    3. Blake H,
    4. Koh MD,
    5. Swift I,
    6. Arnaout A,
    7. Temple L, et al.
    Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg. 2010; 97: 1407–15.
    OpenUrlPubMed
  31. 31.↵
    2. Halefoglu A-M,
    3. Yildirim S,
    4. Avlanmis O,
    5. Sakiz D,
    6. Baykan A.
    Endorectal ultrasonography versus phased-array magnetic resonance imaging for preoperative staging of rectal cancer. World J Gastroenterol. 2008; 14: 3504–10.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Baretti M,
    3. Le DT.
    DNA mismatch repair in cancer. Pharmacol Ther. 2018; 189: 45–62.
    OpenUrlCrossRef
  33. 33.↵
    2. Parry S,
    3. Win AK,
    4. Parry B,
    5. Macrae FA,
    6. Gurrin LC,
    7. Church JM, et al.
    Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011; 60: 950–7.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section